LifeSci Capital Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
I'm PortAI, I can summarize articles.
LifeSci Capital's Oliver McCammon maintains a Buy rating for Janux Therapeutics Inc with a $60 price target. McCammon, who covers the Healthcare sector, has an average return of 114.4% and a 53.13% success rate. Clear Street's Kaveri Pohlman also issued a Buy rating, while TR | OpenAI – 4o reiterated a Hold rating. The report highlights TipRanks' Cyber Monday sale offering 60% off Premium subscriptions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments